KeViRx develops small molecule therapeutics for cancer and other diseases. Our lead compound, KVX-053, is a potent allosteric and selective phosphatase of regenerating liver 3 (PRL3, or PTP4A3) inhibitor. This target phosphatase is overexpressed in various cancers, including drug resistant ovarian cancer, and is believed to activate pathways enabling cancer cell migration and metastasis. KVX-053 displays promising activity in cell-based models of ovarian cancer and leukemia, as well as anti-tumor activity in in vivo models of ovarian cancer and acute myeloid leukemia.